Clinical Trials Browser

Pathologic Complete Response × tislelizumab × Gastrointestinal × Clear all

NCT06647680 2026-03-06

Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01）

Phase 2 Recruiting

Gastrointestinal

Pathologic Complete Response, Rectal Neoplasms